Advertisement

CNS Drugs

, Volume 22, Issue 3, pp 199–212 | Cite as

Pharmacological Control of Acute Agitation

Focus on Intramuscular Preparations
  • Dan L. Zimbroff
Review Article

Abstract

Acute agitation in the psychiatric emergency setting is a common presentation, which can endanger the patient, caregivers and professional staff. Rapid and effective treatment, followed by ongoing evaluation and maintenance treatment where appropriate, is key to circumvent negative outcomes. Nonpharmacological measures are the first step in treating the acutely agitated patient, and include verbal intervention and physical restraint. Pharmacological treatment is often required to ensure the safety of the patient, caregivers and the treatment team. The need for drug delivery in uncooperative patients favours the use of intramuscular preparations for the acutely agitated patient. Intramuscular treatment options include benzodiazepines, conventional antipsychotics and atypical antipsychotics. Each of these medications offers a unique pharmacological profile that must be considered when treating acutely agitated patients, who may be unwilling or unable to accurately communicate their co-morbid conditions and concomitant medications.

Keywords

Haloperidol Olanzapine Aripiprazole Atypical Antipsychotic Ziprasidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Editorial support was provided by Annie Neild at PAREXEL, funding for which was provided by Pfizer Inc. Dr Zimbroff has received consultancy fees from Pfizer, Bristol Myers Squibb (BMS) and Eli Lilly & Co; received honoraria for speaking for Pfizer and BMS; received research study grants from Pfizer, Eli Lilly & Co. and BMS; and, in conjunction with his research activities, has received payments from Pfizer, Eli Lilly & Co. and BMS.

Unfortunately, Dr Zimbroff passed away before the page proofs were available; therefore, in the absence of a co-author, Annie Neild of PAREXEL and Elizabeth Pappadopulos of Pfizer Inc. approved the proofs for publication.

References

  1. 1.
    Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004; 26(1): 42–9PubMedCrossRefGoogle Scholar
  2. 2.
    Callegari CM, Menchetti M, Croci G, et al. Two years of psychogeriatric consultations in a nursing home: reasons for referral compared to psychiatrists’ assessment. BMC Health Serv Res 2006; 6: 73PubMedCrossRefGoogle Scholar
  3. 3.
    Citrome L. Atypical antipsychotics for acute agitation: new intramuscular options offer advantages. Postgrad Med 2002; 112(6): 85–6PubMedCrossRefGoogle Scholar
  4. 4.
    Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005; 10(9): 1–15PubMedGoogle Scholar
  5. 5.
    Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000; 61Suppl. 14: 5–10PubMedGoogle Scholar
  6. 6.
    Hazlett SB, McCarthy ML, Londner MS, et al. Epidemiology of adult psychiatric visits to US emergency departments. Acad Emerg Med 2004; 11(2): 193–5PubMedGoogle Scholar
  7. 7.
    Dhossche DM, Ghani SO. Who brings patients to the psychiatric emergency room? Psychosocial and psychiatric correlates. Gen Hosp Psychiatry 1998; 20(4): 235–40PubMedCrossRefGoogle Scholar
  8. 8.
    Keck Jr PE, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001; 85(3): 645–61, ixPubMedCrossRefGoogle Scholar
  9. 9.
    Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65(9): 1207–22PubMedCrossRefGoogle Scholar
  10. 10.
    Sourial R, McCusker J, Cole M, et al. Agitation in demented patients in an acute care hospital: prevalence, disruptiveness, and staff burden. Int Psychogeriatr 2001; 13(2): 183–97PubMedCrossRefGoogle Scholar
  11. 11.
    Zealberg JJ, Brady KT. Substance abuse and emergency psychiatry. Psychiatr Clin North Am 1999; 22(4): 803–17PubMedCrossRefGoogle Scholar
  12. 12.
    Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: treatment of behavioral emergencies. Expert Consensus Panel for Behavioral Emergencies. Postgrad Med 2001; Spec No: 1-88, quiz 89-90Google Scholar
  13. 13.
    Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11Suppl. 1: 5–108PubMedCrossRefGoogle Scholar
  14. 14.
    Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61Suppl. 14: 11–20PubMedGoogle Scholar
  15. 15.
    Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am 2005; 28(3): 701–11PubMedCrossRefGoogle Scholar
  16. 16.
    Rocca P, Villari V, Bogetto F. Managing the aggressive and violent patient in the psychiatric emergency. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(4): 586–98PubMedCrossRefGoogle Scholar
  17. 17.
    Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 2003; 9(1): 39–58PubMedCrossRefGoogle Scholar
  18. 18.
    Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006; 12(1): 30–40PubMedCrossRefGoogle Scholar
  19. 19.
    Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med 2005; 23(6): 767–76PubMedCrossRefGoogle Scholar
  20. 20.
    Ntais C, Pakos E, Kyzas P, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2005; (3): CD005063Google Scholar
  21. 21.
    Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52(4): 177–80PubMedGoogle Scholar
  22. 22.
    Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12(3): 175–9PubMedCrossRefGoogle Scholar
  23. 23.
    Alexander J, Tharyan P, Adams C, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry 2004; 185: 63–9Google Scholar
  24. 24.
    Richards JR, Deriet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998; 16(4): 567–73PubMedCrossRefGoogle Scholar
  25. 25.
    TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327(7417): 708–13CrossRefGoogle Scholar
  26. 26.
    Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med 2006; 47(1): 61–7PubMedCrossRefGoogle Scholar
  27. 27.
    Nobay F, Simon BC, Levitt MA, et al. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 2004; 11(7): 744–9PubMedGoogle Scholar
  28. 28.
    Dorevitch A, Katz N, Zemishlany Z, et al. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999; 156(1): 142–4PubMedGoogle Scholar
  29. 29.
    Rund DA, Ewing JD, Mitzel K, et al. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med 2006; 31(3): 317–24PubMedCrossRefGoogle Scholar
  30. 30.
    van Leeuwen AM, Molders J, Sterkmans P, et al. Droperidol in acutely agitated patients: a double-blind placebo-controlled study. J Nerv Ment Dis 1977; 164(4): 280–3PubMedCrossRefGoogle Scholar
  31. 31.
    Rosen CL, Ratliff AF, Wolfe RE, et al. The efficacy of intravenous droperidol in the prehospital setting. J Emerg Med 1997; 15(1): 13–7PubMedCrossRefGoogle Scholar
  32. 32.
    Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45(7): 298–9Google Scholar
  33. 33.
    Thomas Jr H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992; 21(4): 407–13PubMedCrossRefGoogle Scholar
  34. 34.
    Inapsine [prescribing information]. Decatur (IL): Taylor Pharmaceuticals, 2006Google Scholar
  35. 35.
    Guy JM, Andre-Fouet X, Porte J, et al. Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol [in French]. Ann Cardiol Angeiol (Paris) 1991; 40(9): 541–5Google Scholar
  36. 36.
    Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79(5): 983–6PubMedCrossRefGoogle Scholar
  37. 37.
    Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15(4): 335–40PubMedCrossRefGoogle Scholar
  38. 38.
    Bieniek SA, Ownby RL, Penalver A, et al. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18(1): 57–62PubMedGoogle Scholar
  39. 39.
    Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989; 146(12): 1598–601PubMedGoogle Scholar
  40. 40.
    Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl 1994; 380: 14–20PubMedCrossRefGoogle Scholar
  41. 41.
    Caine ED. Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatry 2006; 67Suppl. 10: 22–31PubMedGoogle Scholar
  42. 42.
    Crowner ML, Douyon R, Convit A, et al. Akathisia and violence. Psychopharmacol Bull 1990; 26(1): 115–7PubMedGoogle Scholar
  43. 43.
    King DJ, Burke M, Lucas RA. Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995; 167(4): 480–2PubMedCrossRefGoogle Scholar
  44. 44.
    Kitayama H, Kiuchi K, Nejima J, et al. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55(4): 259–62PubMedCrossRefGoogle Scholar
  45. 45.
    Zyprexa [prescribing information]. Indianapolis (IN): Eli Lilly and Company, 2005Google Scholar
  46. 46.
    Geodon [prescribing information]. New York (NY): Pfizer Inc, 2005Google Scholar
  47. 47.
    Abilify [package insert]. Princeton (NJ): Bristol-Myers Squibb Company, 2006Google Scholar
  48. 48.
    Canas F. Management of agitation in the acute psychotic patient: efficacy without excessive sedation. Eur Neuropsycho-pharmacol 2007; 17Suppl. 2: S108–14CrossRefGoogle Scholar
  49. 49.
    Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005; 162(5): 939–46PubMedCrossRefGoogle Scholar
  50. 50.
    Warrington L, Loebel A, Siu C, et al. Early onset of antipsychotic action in the treatment of acutely agitated patients with schizophrenia [poster NR445]. American Psychiatric Association 159th Annual Meeting; 2006 20–25 May: Toronto (ON)Google Scholar
  51. 51.
    Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2): 128–34CrossRefGoogle Scholar
  52. 52.
    Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1): 12–8PubMedCrossRefGoogle Scholar
  53. 53.
    Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27(2): 140–4PubMedCrossRefGoogle Scholar
  54. 54.
    Kohen I, Preval H, Southard R, et al. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother 2005; 3(4): 240–5PubMedCrossRefGoogle Scholar
  55. 55.
    Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry 2000; 61(12): 933–41Google Scholar
  56. 56.
    Brook S, Waiden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005; 178(4): 514–23CrossRefGoogle Scholar
  57. 57.
    Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006; 67(4): 638–42PubMedCrossRefGoogle Scholar
  58. 58.
    Daniel DG, Brook S, Warrington LE, et al. IM ziprasidone in agitated patients with bipolor diagnosis [abstract]. Presented at Institute of Psychiatric Services 2004 Annual Meeting; 2004 Oct 6–10; Atlanta (GA)Google Scholar
  59. 59.
    Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59(5): 441–8PubMedCrossRefGoogle Scholar
  60. 60.
    Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158(7): 1149–51PubMedCrossRefGoogle Scholar
  61. 61.
    Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21(4): 389–97PubMedCrossRefGoogle Scholar
  62. 62.
    San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006; 21(8): 539–43PubMedCrossRefGoogle Scholar
  63. 63.
    Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26(4): 494–504PubMedCrossRefGoogle Scholar
  64. 64.
    Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003; 25(5): 1420–8PubMedCrossRefGoogle Scholar
  65. 65.
    Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003; 48(11): 716–21PubMedGoogle Scholar
  66. 66.
    Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry 2005; 66(12): 1614–5PubMedCrossRefGoogle Scholar
  67. 67.
    Bymaster FP, Hemrick-Luecke SK, Perry KW, et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996; 124(1–2): 87–94CrossRefGoogle Scholar
  68. 68.
    Bellnier TJ. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm 2002; 59(17 Suppl. 5): S12–8PubMedGoogle Scholar
  69. 69.
    Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188(3): 281–92CrossRefGoogle Scholar
  70. 70.
    Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006; 22(11): 2209–19PubMedCrossRefGoogle Scholar
  71. 71.
    Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68(1): 111–9PubMedCrossRefGoogle Scholar
  72. 72.
    First DataBank, Inc., San Bruno, CA, USA. Blue Book AWP, 2006 [online]. Available from URL: http://www.firstdatabank.com [Accessed 2008 Jan 22]

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Dan L. Zimbroff
    • 1
  1. 1.Pacific Clinical Research Medical GroupUplandUSA

Personalised recommendations